TXG CEO Serge Saxonov sold 28,893 shares for $709,057.47 via pre-arranged 10b5-1 plan
Serge Saxonov, CEO of 10x Genomics, executed 2 separate sales totaling 28,893 shares for $709,057.47 on 2026-05-22 and 2026-05-26 at blended average price $24.54. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-11-29, meaning the sales were scheduled and not discretionary trading decisions. Post-transaction, Saxonov retains 1,138,380 shares, representing a -2.5% reduction in his holdings. The current stock price is $25.51, modestly above the transaction prices, and the stock is up 14.5% over the past 30 days and 15.3% over 90 days. The company is currently unprofitable with negative net income of $-13,470,000.00 in the latest quarter, though revenue of $150,843,000.00 grew 5.2% annually. Since this sale was pre-arranged under a 10b5-1 plan rather than discretionary, the timing does not reflect the insider's current market assessment.